Supercharging Discovery with Novel Technologies to Deconvolute MOAs, Elucidate Target Biology & Accelerate GPCR Drug Design
The GPCR field is entering its next phase of innovation. As biopharma looks beyond GLP-1 for the next breakthrough therapeutic opportunity, advances in AI, structural biology, next-generation screening platforms, and signaling science are transforming how researchers discover, validate, and drug GPCR targets. Yet critical challenges remain, from de-risking orphan receptors and predicting functional activity to translating complex GPCR biology into differentiated medicines.
The 6th GPCRs-Targeted Drug Discovery Summit is the industry's only dedicated meeting focused exclusively on advancing GPCR drug discovery across targets, modalities, and therapeutic areas. Bringing together leaders from Eli Lilly, Pfizer, Roche, Recursion Pharmaceuticals, Alphamol, LEMBAS, Kainova Therapeutics, Duke University, University of Miami, and more, this is your opportunity to benchmark the latest advances in AI-enabled discovery, target validation, signaling biology, structural drug design, and next-generation GPCR therapeutics.
Whether you're searching for the next target beyond GLP-1, evaluating emerging modalities, or looking to accelerate your GPCR pipeline, join 80+ industry and academic experts shaping the future of GPCR drug discovery.
When you are in the business of developing drugs it is important to know what is going on right now and where the future might lie. The GPCR summit is the right place for that.
Benjamin Pelcman, Scientific Advisor, Atrogi
The intimate scale of this meeting creates an excellent opportunity for valuable discussion and networking.
David O'Connell, Founder, SelekTx Precision Biologics
An excellent opportunity for industry partners to learn about cutting-edge science that can impact their discovery pipelines and foster connections with academic partners.
Sivaraj Sivaramakrishnan, Professor, University of Minnesota
Explore The Full Event Guide
- Explore the complete 2027 agenda, featuring a dedicated focus day deep dive into emerging discovery technologies alongside two days of cutting-edge GPCR science.
- Preview exclusive sessions from Eli Lilly, Pfizer, Roche, Recursion Pharmaceuticals, Alphamol, and University of Miami.
- Discover how the industry is tackling GPCR discovery's biggest challenges, from target validation and signaling biology to AI accountability and biased agonism.
- See who you'll be networking with, including scientific decision-makers from leading pharma, biotech, and academic organizations.
- Identify the sessions, speakers, and networking opportunities most relevant to your programs before you attend.
Official Partners 2026
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover the latest advances in AI-enabled discovery, target validation, signaling biology, and emerging GPCR therapeutics across three days of scientific discussion.
Partner With Us
Showcase your expertise to a highly targeted audience of scientists and decision-makers actively seeking technologies, services, and partners to accelerate GPCR discovery.
Join the GPCR Community
Connect with leading pharma, biotech, and academic experts tackling the biggest challenges and opportunities shaping the future of GPCR drug discovery.